ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Agilent Technologies is working with Florida International University’s department of chemistry and biochemistry and its International Forensic Research Institute to identify and characterize designer drugs. The partners will develop screening methods based on advanced chromatography and mass spectrometry with the goal of being able to detect about 300 such drugs, which are synthesized to circumvent existing laws. Traditional immunoassay drug-screening methods can’t detect most designer drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X